Chester County News and Community Website
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) recently presented compelling data on its investigational hepatitis B therapies, imdusiran and AB-101, at the European Association for the Study of the …
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for presentation at the European Association for the Study of the Liver …
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced promising new data from its IM-PROVE I Phase 2a clinical trial, suggesting significant advancements in treatment for chronic hepatitis B …
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment Read More WARMINSTER, PA and OXFORD, United Kingdom — Arbutus Biopharma Corporation and Barinthus Biotherapeutics recently unveiled encouraging preliminary results from their Phase 2a IM-PROVE II clinical trial at the American Association …
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released new data from their Phase 2a clinical trial, IM-PROVE I, revealing that imdusiran, their RNAi therapeutic, in combination with a …
Advancing Towards a Functional Cure: Promising Results in Hepatitis B Treatment Read More